ArticleFrontiers in endocrinology2025
Obesity metabolomics signature in children: associations with metabolic abnormalities and potential biomarkers.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The global rise in childhood obesity has heightened its recognition as a major public health concern, with obesity being an independent risk factor for metabolic abnormalities. However, the metabolomics mechanisms linking pediatric obesity to metabolic abnormalities remain unclear. Methods: This case-control study utilized data from a 2023 cross-sectional survey of children aged 9-18 years in Guangzhou, China. A total of 246 participants were included, with 123 obese and 123 normal-weight participants matched for age and sex. Serum metabolomics profiling was performed via LC-MS. A dual machine learning approach combining penalized multivariable Least Absolute Shrinkage and Selection Operator (LASSO) regression and random forest with recursive feature elimination (RF-RFE) was employed to identify robust obesity-associated serum metabolites independent of metabolic abnormalities and logistic regression was employed to construct the obesity metabolomics signature (OB-MS) model. Multivariable logistic regression was used to assess the associations between the OB-MS and metabolic abnormalities and their components, including hyperglycemia, hypertension, hypertriglyceridemia, and reduced HDL-C. Results: Among 934 detected metabolites, 10 core metabolites were selected to construct the OB-MS, which showed high discriminative power, with an ROC-AUC of 0.986 in the testing set. Elevated OB-MS scores were significantly associated with increased risks of metabolic abnormalities, particularly hypertension and hypertriglyceridemia. Additionally, six key metabolites, including oxidative stress markers and dipeptides, were independently associated with metabolic abnormalities. Conclusions: This study established a pediatric obesity-specific metabolomics signature (OB-MS), implicating oxidative stress, protein catabolism, and glucocorticoid metabolism in obesity-related metabolic abnormalities. These finding illustrate the metabolic mechanisms underlying the relationship between childhood obesity and metabolic abnormalities and provide new scientific support for early and precise prevention of metabolic abnormalities in children. Further longitudinal studies and experimental validation are warranted to elucidate its biological mechanisms and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.